

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**PHASE III CLINICAL TRIAL OF SYS 6010 IN COMBINATION WITH
ENLONSTOBART FOR THE ADJUVANT TREATMENT OF RESECTED STAGE
II-IIIB NON-SMALL CELL LUNG CANCER
WITH ACTIONABLE GENOMIC ALTERATION-NEGATIVE STATUS AND
WITHOUT ACHIEVING MPR OFFICIALLY INITIATED IN CHINA**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has officially initiated a randomised, controlled, open-label Phase III clinical trial (SYS 6010-015) in China to evaluate the safety and efficacy of SYS 6010 in combination with a PD-1 monoclonal antibody (Enlonstobart) versus a PD-(L)-1 monoclonal antibody in the adjuvant treatment of patients with completely resected stage II-III B non-small cell lung cancer who have no actionable genomic alterations and have not achieved MPR, with the enrolment of the first participant expected to be completed in July 2026.

SYS 6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (“**EGFR**”) developed by the Group, which is composed of a humanised anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker. This drug specifically binds to EGFR on the surface of tumour cells and releases the cytotoxic payload intracellularly upon internalisation, thereby exerting anti-tumour effects. Enlonstobart Injection (recombinant fully human anti-PD-1 monoclonal antibody injection) is a humanised IgG4 variant monoclonal antibody targeting programmed cell death protein-1 (PD-1), which is indicated for the treatment of malignant tumours in various human organs and tissues.

SYS 6010–015 is a randomised, open-label, multi-centre, Phase III clinical trial aimed at evaluating the safety and efficacy of SYS 6010 in combination with Enlonstobart as an adjuvant treatment for patients with completely resected stage II-III B non-small cell lung cancer who have no actionable genomic alterations and have not achieved MPR. Previously, the Group received an opinion from the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China in June 2026, granting approval to conduct this clinical trial. Currently, the recruitment and screening of subjects are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 30 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.